Moderna's chief medical officer on 3-in-1 vaccine: "Great news for global public health"
Moderna is working on a candidate against RSV, flu, and Covid-19, all in one vaccine – and CMO Paul Burton points out the many advantages of combining such targets for patients.
by christian bundgaard, translated by daniel pedersen
Last week, Moderna took a big step toward the future market for vaccines against respiratory syncytial virus, RSV, when presenting strong data from phase III study ConquerRSV.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: New Moderna RSV data bodes well for Bavarian Nordic
For subscribers
